High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma

Kenny Yu(Memorial Sloan Kettering Cancer Center), Brian Bigger(University of Manchester), Brian A. Telfer(University of Manchester), Ian Peers(AstraZeneca (United Kingdom)), Amir Saam Youshani(University of Manchester), Kaye J. Williams(University of Manchester), Peter Cueppens(AstraZeneca (United Kingdom)), Joanna Dutko-Gwóźdź, Gareth Griffiths(NIHR Evaluation Trials and Studies Coordinating Centre), Deniz Beyit, Omar Pathmanaban(Manchester Academic Health Science Centre), Ian Kamaly-Asl(Royal Manchester Children's Hospital), Jessica Taylor(University of Manchester), Roderick S. P. Benson, Catherine McBain(Unknown)
PLoS ONE
March 2, 2018
10.1371/journal.pone.0193694
Cited by 17

Related Papers

Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
|The Lancet|2007|570
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
|The Lancet|2017|401
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity
|Nature Cancer|2021|334
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
|The Lancet Oncology|2021|333